US30063P1057 - Common Stock
57.53 -1.96 (-3.29%)
After market: 57.53 0 (0%)
EXACT SCIENCES CORP
NASDAQ:EXAS (2/23/2024, 7:00:01 PM)After market: 57.53 0 (0%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,300 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The firm is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test and COVID-19 Testing. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
EXACT SCIENCES CORP
5505 Endeavor Lane
Madison WISCONSIN 53719
CEO: Kevin T. Conroy
EXAS earnings call for the period ending December 31, 2023.
Exact Sciences beats expectations with Q4 earnings. Revenue of $647M, a 17% increase.
This company hasn't performed well in the past 12 months.
Here you can normally see the latest stock twits on EXAS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.